1stOncology™: Cancer Intelligence Service – Page 5917 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

On November 22, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City, New York (Press release, Akebia, NOV 22, 2022, View Source/news-releases/news-release-details/akebia-therapeutics-participate-piper-sandler-34th-annual" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-participate-piper-sandler-34th-annual" rel="nofollow">View Source [SID1234624401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

John P. Butler, Chief Executive Officer of Akebia Therapeutics, will participate in a fireside chat on Tuesday, November 29 at 2:30 p.m. ET.

A webcast of the fireside chat will be available through the Investors section of Akebia’s website at View Source for approximately 90 days following the conference.

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

On November 22, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:30 a.m. ET (Press release, Supernus, NOV 22, 2022, View Source [SID1234624386]).

The conference will take place November 29 – December 1, 2022 at the Lotte New York Palace in New York City. Investors interested in arranging a meeting with company management should contact the Piper Sandler conference coordinator. A live audio webcast of the fireside chat can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company’s website following the conference.

SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference

On November 21, 2022 SIWA Therapeutics reported the aging-related and cancer cell-derived oxidatively-stressed tumor microenvironment and other cell damages drive cell senescence and other oxidative cellular responses (Press release, SIWA Therapeutics, NOV 22, 2022, View Source [SID1234624385]). Tumor fibrosis reduces the effectiveness of anti-cancer immune responses and senescent cells (SCs), in turn, promote immune suppression, tumor progression, and metastasis. Hence, according to a study conducted by Translational Genomics Research Institute on behalf of SIWA Therapeutics, Inc. as presented by Dr. Gabriela Rossi, Chief Research Officer of SIWA Therapeutics, Inc. ("SIWA") at the AACR (Free AACR Whitepaper) Special Conference: Aging and Cancer November 17 -20, 2022, targeting damaged cells, including SCs and cancer cells, with SIWA318H, presents an attractive approach for cancer therapy.

SIWA318H is a monoclonal antibody that selectively targets an advanced glycation end product oxidative stress biomarker on the surface of dysfunctional cells exhibiting both (a) aerobic glycolysis and b) oxidative stress. The SIWA318H biomarker is associated with cancer cells, SCs, oxidatively-damaged cells, and infected cells. SIWA318H has been shown to exhibit strong binding to pancreatic cancer patient derived xenograph tumors as demonstrated by immunochemistry bind to an ADCC inducing human IgG FcγR3 receptor to enable ADCC as a mechanism of action for SIWA318H.

In an in vivo study using a humanized mouse xenograft model for pancreatic cancer, it was shown thattreatment with SIWA318H (both high and low dose groups) statistically significantly reduced tumor growth compared to the isotype antibody control group (P < 0.0001). In addition, there was a significantly higher number of mice that had complete remission in the SIWA318H-treated groups compared to the isotype control group: 37.5% in high dose group (P = 0.0325) and 43.8% in low dose group (P = 0.0143). Moreover, mice treated with SIWA318H had a median overall survival of > 45 days compared to 26 days for the isotype control mice. There was no difference in animal body weight between the SIWA318H-treated mice and the isotype control mice indicating that the treatment with SIWA318H was well tolerated.

Immunohistochemical analysis of tumor tissues taken from the in vivo study showed that SIWA318H treatment significantly reduced (a) tumor fibrosis as measured by the area of αSMA+ staining and (b) the number of senescent cells in the tumor stroma as measured by the number of p16INK4a positive cells in αSMA+ areas.

In summary, the SIWA results demonstrate that SIWA318H is a novel antibody that exhibits potent preclinical antitumor activity against pancreatic cancer. SWA318H is currently under development for a first-in-human clinical trial.

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

On November 18, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA) (the "Company" or "Cassava Sciences"), a clinical-stage biotechnology company focused on Alzheimer’s disease, reported that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offering (Press release, Pain Therapeutics, NOV 22, 2022, View Source [SID1234624384]). The closing of the offering is expected to occur on or about November 22, 2022, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company’s lead drug candidate for the treatment of Alzheimer’s disease.

The shares of common stock are being offered by Cassava Sciences pursuant to an automatic "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 10, 2021 and became effective immediately upon filing, and the prospectus contained therein. The offering will be made only by means of a prospectus supplement that forms a part of the registration statement.

A prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at View Source or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

Corporate Presentation

On November 22, 2022 Oncosec presented its corporate presentation (Presentation, OncoSec Medical, NOV 22, 2022, View Source [SID1234624383]).